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Abstract
A cohort of individuals (n = 136) with lesions as severe
as atrophic chronic gastritis (ACG) was cross-section-
ally evaluated for the validity assessment of pepsin-
ogen I (PGI) and pepsinogen II (PGII) serum levels for
the diagnosis of intestinal metaplasia (IM) and gastric
dysplasia. PGI/PGII ratio [median (range)] was 4 (0.5–
7.5) in patients with ACG (n = 35); 4.6 (1.9–6.8) in type I
IM (n = 18); 4.2 (1.4–5.9) in type II or type III IM limited
to the antrum and incisura (n = 20); 2.4 (0.4–5.6) in
extensive incomplete IM (n = 38); and 1.3 (0.4–6.4) in
low-grade dysplasia (n = 23) (P = .002). Using
histopathologic data as a reference test, the area
under the receiver operating characteristic curves
(CI 95%) was 0.73 (0.64–0.82) for extensive IM, 0.72
(0.58–0.85) for the diagnosis of dysplasia, and 0.81
(0.66–0.95) for the diagnosis of high-grade dysplasia.
Using a PGI/PGII ratio of V3 as the cutoff for dysplasia
diagnosis, the sensitivity was 70% (62–78%), the
specificity was 65% (57–73%), and the negative
predictive value estimates were over 90%. No differ-
ences in PG levels according to age or gender were
observed. Helicobacter pylori did not significantly
influence validity measurement estimates. PGI/PGII
serum level ratio can be used even in the manage-
ment of patients with a high a priori probability for a
positive test. It may be useful for the exclusion of
more advanced lesions (extensive IM and neoplastic
lesions).
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Introduction
At least for the intestinal type of gastric adenocarcinoma, a
cascade of histopathologic lesions has been defined: chron-
ic gastritis, atrophic chronic gastritis (ACG), intestinal meta-
plasia (IM), and dysplasia [1]. Although the diagnosis of these
lesions and the cost-effectiveness of their management are still
to be clearly defined, the follow-up of patients with such lesions
may lead to the diagnosis of gastric cancer at an early stage,
thus improving patients’ survival rate [2,3]. The identification of
such lesions depends on invasive tests such as upper gastro-
intestinal endoscopy, and it represents a challenge because
they are scattered and multifocal.
Human pepsinogens I (PGI) and II (PGII) are proenzymes of
pepsin—an endoproteinase of gastric juice. PGI is secreted
mainly by chief cells in the fundic mucosa [4], whereas PGII is
also secreted by the pyloric glands and the proximal duodenal
mucosa [5]. Helicobacter pylori–related gastric atrophy and
further changes tend to start at the antrum and antrum–corpus
junction and the antral lesser curvature and incisura, and
progress proximally in the distal corpus and, finally, the prox-
imal corpus. In this way, serum PGI and PGII concentrations
and the ratio between PGI and PGII may be related to the
histologic and functional status of the gastric mucosa [6–16].
In fact, the ‘‘pepsinogen test’’ has been used [11,12,15,16]
as a noninvasive ‘‘serologic biopsy’’ to select and improve
patient compliance to generalized cancer screening programs
in Japan.
Because such mass screening programs may not be feasi-
ble in Western countries, we aimed to determine the validity of
the pepsinogen test for gastric epithelial dysplasia and IM
diagnosis in a set of individuals with known gastric lesions
as severe as ACG, hypothesizing its consistency even with a
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high a priori probability for a positive test. If it is valid, it may
circumvent the problem of invasiveness of endoscopy and
may add useful information to an as-yet-undefined schedule
to be used even in Western countries for patients at high risk
for gastric cancer.
Methods
Participants and Type of Study
A cross-sectional evaluation was performed on a cohort
of 136 individuals [37%males, with a median age of 61 years
old (minimum 26–maximum 75)] under follow-up at our
institution after the diagnosis of gastric epithelial lesions
associated with gastric cancer at least as severe as ACG
(ACG, IM, or gastric epithelial dysplasia). No differences in
age, gender, and time of follow-up were found according to
histopathologic data.
After informed consent was given, the patients’ data were
analyzed and each patient submitted to 1) histopathologic
assessment of endoscopic biopsies (‘‘gold standard’’); 2)
blood collection for serum pepsinogen I (PGI) and pepsino-
gen II (PGII) determination; and 3) H. pylori infection status
assessment, which was also considered because it is a
recognized risk factor for gastric mucosal inflammation and
atrophy and thus a possible confounder to consider in PG
validity [17].
This study was fully approved by the ethical committee
of the Instituto Portugueˆs de Oncologia, Centro do Porto
(Porto, Portugal).
Histopathologic Assessment of Endoscopic Biopsy
Specimens (Reference Test or Gold Standard)
All participants were submitted to magnification chro-
moendoscopy using methylene blue (1%) as vital staining
for IM mucosa and an Olympus Q240Z magnification endo-
scope (Olympus Corp., Tokyo, Japan) [18]. From each adult,
a minimum of five endoscopic gastric biopsies was obtained
from areas with differences in color or homogeneity, or
randomly in the antrum, incisura, and corpus if no lesion
was observed. Specimens were evaluated independently
by two pathologists.
Atrophy was defined as the disappearance of normal
glands in a determinate area of the stomach [19]. IM was
classified as complete (type I) and incomplete (type II or III),
according to sulpho staining or syalomucin staining [20]. IM
extension [21,22] was estimated as a proportion of speci-
mens with IM. As gastric mucosa specimens collected from
the antrum, incisura, and corpus were available, an index for
IM extension estimate was devised as follows: 1+/3 (only one
of the three biopsies performed showed IM in histopathologic
evaluation); 2+/3 (two of three specimens with IM); and 3+/3
(histopathologic evaluation of all specimens collected dem-
onstrated IM, therefore representing multifocal extensive IM
from the antrum to the corpus). According to the Vienna
classification [23], low-grade dysplasia (LGD) was consid-
ered as low-grade noninvasive neoplasia. High-grade dys-
plasia (HGD) was considered as noninvasive carcinoma and
was analyzed as high-grade neoplasia– invasive carcinoma.
Each subject was assigned a global histologic diagnosis
to be used as the gold standard or reference test for the
pepsinogen test of validity measurements. Seven groups
were defined based on the presence of IM and its extension
or dysplasia:
- ACG with no IM or dysplasia in any of the specimens
collected (n = 35)
- type I IM limited to the antrum and/or the incisura (1+ or
2+/3) (n = 4)
- extensive multifocal type I IM (n = 14)
- 1+ or 2+/3 grade type II/III IM (n = 22)
- extensive 3+/3 grade type II/III IM (n = 38)
- patients with lesions as severe as LGD (n = 23)
- individuals with lesions as severe as high-grade non-
invasive neoplasia or invasive carcinoma (n = 11).
No differences in statistical significance were found in
age or gender distribution or time during follow-up across the
groups defined above.
Pepsinogen Serum Level Determination
Approximately 40 ml of blood was collected from each
fasting subject. The blood was centrifuged at 3000 rpm for
5 minutes and the serum aliquot was stored immediately
at 20jC.
Using a solid-phase two-step sandwich enzyme immuno-
assay method (E PLATE Eiken PEPSINOGEN; Eiken
Chemical Co., Ltd., Tokyo, Japan), all sera were analyzed
for the determination of PGI and PGII concentrations.
First, PGI or PGII standards or the sample (20 ml) and buffer
(100 ml) were placed on antipepsinogen–coated microplates
and incubated at 15jC to 30jC for 110 minutes. After
cleaning the reaction mixture by washing, enzyme-labeled
antipepsinogen was added (for 5 minutes) to the microplate
and incubated at 15jC to 30jC for 55 minutes. After the
reaction was completed, the plate was washed and the
enzyme reaction was allowed to proceed with the addition
of a substrate. The absorbance was then measured by using
a microplate spectrophotometer [492 nm (480–500 nm)].
Pepsinogen (I or II) levels in the sample were obtained after
a standard curve was drawn. Each sample was evaluated
twice for each patient; a coefficient of variation of <15%
was considered acceptable.
Possible ranges according to the supplier’s PGI and PGII
assay results can range from 2 to 200 ng/ml, and from 1 to
100 ng/ml, respectively.
H. pylori Infection Status
After gastric biopsies were obtained, they were evaluated
for H. pylori infection using Giemsa, immunohistochemistry,
and culture. In a previous report, we locally validated specific
serum anti–H. pylori antibody levels and validity measures
[the best cutoff is defined as serum-specific anti–H. pylori
immunoglobulin G (IgG) antibodies z41 mg/ml] [24]. As IM
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probably may not allow H. pylori to survive [24–27], in this
study, patients were considered infected by H. pylori if at
least one culture medium was positive or both bacterial
culture returns were positive, or if serum IgG H. pylori anti-
body levels were considered positive. Thirty-eight percent of
patients included were considered infected by H. pylori.
Personal clinical files of all participants were reviewed and
previous H. pylori eradication therapy was excluded.
Mucosal specimens were collected and then conserved
in a transport medium (Portagerm Pylori; bioMe´rieux, Marcy
I’etoile, France) until homogenization under aseptic condi-
tions in 1.5 ml of sterile medium broth (Brain Heart Infusion;
BioGerm, Maia, Portugal). Both nonselective (Columbia
agar, with 5% sheep blood; bioMe´rieux) and selective (Pylori
agar; bioMe´rieux) media were used and placed under micro-
aerobic conditions (10% CO2 and 10% O2) in a gas-regulat-
ed incubator at 37jC and incubated for 5 to 10 days. All
small, grey, and translucent colonies obtained were studied.
Biochemical analyses were performed for catalase, oxidase,
and urease activity, and Gram stain.
All patients’ sera were tested for IgG with Serion ELISA
Classic H. pylori kits (ELISA Classic Helicobacter pylori;
Virion/Serion GmbH, Wu¨rzburg, Germany). The assays
were performed in accordance with the manufacturer’s
instructions and without knowledge of the adults’ H. pylori
status. Immunoglobulin titer was interpreted from a graph
obtained from the semilogarithmic axes analysis of the
manufacturer’s standard curve.
Statistical Analysis
Statistical Package for Social Sciences software (SPSS
9.0 Package Facility) was used for data support and analy-
sis. Nonparametric tests were used to assess differences
across groups of patients [see Histopathologic Assessment
of Endoscopic Specimens (Reference Test or Gold Stan-
dard) section], namely, PGI, PGII, PGI/PGII ratio, and H.
pylori IgG antibody levels. Receiver operating characteristic
curves were plotted to determine the best cutoff as the
tangent point to the curve parallel to the diagonal of the
graphic. Sensitivity, specificity, predictive values, and likeli-
hood ratio estimates were calculated by considering histo-
pathology as a reference test (gold standard).
Results
Serum Levels of PGI and PGII and PGI/PGII Ratio
According to Histopathologic Lesions
The median levels of PGI and of PGII were 50.6 ng/ml
(ranging from 0 to 200) and 13 ng/ml (2.8–100), respectively.
Table 1 shows PGI and PGII serum level distribution, and
PGI/ PGII ratio according to histopathologic lesions. No
differences with statistical significance were observed in
PGI or PGII distribution. Instead, the PGI/PGII ratio was
significantly (P = .002) lower toward IM, in relation to its
extension, LGD, and more severe lesions. No differences
were observed between patients with ACG and those with
complete IM or 1+ or 2+/3 incomplete IM. Patients with
extensive incomplete IM and those with lesions as severe
as LGD had significantly lower PGI/PGII ratios (P = .005).
Serum levels of PGI and PGII and PGI/PGII ratio did not
vary with age or gender (Table 2). Patients infected with
H. pylori did show higher levels of PGI (median, 52.4 ng/ml)
and PGII (15.3) and lower ratios of PGI/PGII (2.3) (Table 2).
Although H. pylori infection contributes to the decrease in
values of PGI/PGII ratio, more severe lesions such as dys-
plasia have significantly lower levels with (P = .050) or with-
outH. pylori (P = .042) infection (Figure 1). In patients with no
H. pylori infection, PGI/PGII ratio median was 2.7 (0.4–5.6)
in those with extensive IM, and was 1.8 (1.3–6.4) in those
with lesions as severe as dysplasia. Similar results were
found in those infected: 2.4 (1.2–2.4) and 0.7 (0.4–4.9),
respectively.
Best Cutoff for PGI/PGII Serum Level Ratio for the
Diagnosis of Extensive IM and Lesions as Severe as LGD
For the diagnosis of HGD or cancer, the area under the
curve (AUC) was 0.81 (0.66–0.95, 95% CI); for the diagno-
sis of lesions as severe as LGD, AUC = 0.72 (0.58–0.85,
95% CI); and for the diagnosis of lesions more severe than
extensive incomplete IM or LGD, AUC = 0.73 (0.64–0.82,
95% CI) (Figure 2).
Drawn from the curves, the best cutoff was defined (see
Methods section) for validity measurement estimates: PGI/
PGII serum level ratio ofV3.05 for the diagnosis of extensive
IM or dysplastic lesions and PGI/PGII ratio of V3.1 for the
diagnosis of HGD and invasive cancer.
Table 1. PGI and PGII Levels According to Histopathologic Lesions in a Set of Patients at High Risk for Gastric Cancer.
n PGI [ng/ml Median (Range);
Mean (SE)]
PGII [ng/ml Median (Range);
Mean (SE)]
PGI/PGII Ratio [Median (Range);
Mean (SE)]
ACG without IM or dysplasia 35 50.0 (16.7–200); 57.6 (8.4) 12.9 (5.2–94); 19.8 (4.3) 4.0 (0.5–7.5); 3.9 (0.4)
IM as the most severe lesion 78 42.1 (2–151); 47.2 (3.9) 11.2 (4.3–63.4); 14.3 (1.2) 3.5 (0.4–6.8); 3.7 (0.2)
Type I IM as the most severe lesion 18 33.8 (19.7–93); 42.2 (6.9) 9.3 (4.3–63.4); 10.7 (1.7) 4.6 (1.9–6.8); 4.5 (0.5)
Extension: 1+ or 2+/3 4 32.3 (19.7–93); 48.3 (22.6) 5.8 (4.3–13.7); 7.9 (2.9) 5.7 (4.6–6.8); 5.6 (1.6)
Extension: 3+/3 14 35.2 (27.5–59.6); 39.6 (5.0) 10.4 (5.4–63.4); 11.0 (2.1) 4.5 (1.9–5.2); 4.0 (0.4)
Type II/III IM as the most severe lesion 60 39.6 (2–151); 42.4 (4.1) 13.6 (4.3–22); 14.4 (1.2) 3.0 (0.4–5.9); 3.1 (0.2)
Extension: 1+or 2+/3 22 43.5 (26.3–151); 53.8 (10.5) 13.2 (5.9–22); 14.4 (2.8) 4.2 (1.4–5.9); 4.1 (0.4)
Extension: 3+/3 38 35.1 (2–77.1); 37.7 (3.8) 14.0 (4.9–22); 14.4 (1.4) 2.4 (0.4–5.6)*; 2.7 (0.2)
At least LGD 23 24.6 (2.4–60.6); 20.8 (8.0) 11.3 (4.9–15.2); 10.1 (6.3) 1.3 (0.4–6.4)*; 2.3 (0.9)
HGD or invasive carcinoma 11 27.9 (0–192.9); 48.3 (16.8) 14.4 (2.8–100.0); 35.9 (9.1) 1.6 (0.5–5.0)*; 1.7 (0.5)
P* .208 .210 .002*
*Comparison of levels of PGI, PGII, and PGI/PGII ratio according to histopathologic lesions [median (minimum and maximum)], using Kruskal-Wallis test.
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Validity Measures of PGI/PGII Ratio for the Diagnosis of
Gastric Histologic Lesions
Estimates of validity measurements were calculated by
considering the PGI/PGII serum level ratio of V3.0 as a pos-
itive test for the presence of lesions as severe as extensive
incomplete IM (including dysplasia) and for the presence
of gastric mucosal lesions as severe as LGD and HGD or
invasive carcinoma. Two cutoffs other than cutoff levels
were considered for the comparison of PGI/PGII ratios of
V2 and V4. Measures were determined by considering
H. pylori infection status. No differences were observed
(Table 3).
With a PGI/PGII ratio of V3 as a positive test, sensitivity
estimates for the diagnosis of lesions as severe as IM and
HGD varied between 66% and 82%, respectively. All cutoff
levels showed very high negative predictive value estimates.
If we considered H. pylori infection as an alternative positive
test, no significant increase in accuracy is apparent. A slight
increase in sensitivity with a marked decrease in specificity
and negative predictive value occurs (Table 3).
Discussion
Gastric cancer prognosis clearly depends on stage at diag-
nosis [2,28]. Either general population screening or high-risk
individual group follow-up can lead to the diagnosis of (early
gastric) cancer and an improvement in patient survival
[3,29–36]. Mass screening may not be feasible in all
countries, but the follow-up of patients at high risk for gastric
cancer may be useful even in Western countries.
Table 2. Serum Concentrations of PGI, PGII [median (minmax); ng/ml], and PGI/PGII Ratio According to Age, Gender, and H. pylori Infection Status.
PGI [ng/ml Median (Range);
Mean (SE)]
PGII [ng/ml Median (Range);
Mean (SE)]
PGI/PGII Ratio [Median (Range);
Mean (SE)]
Age (r 2) 0.001 0.002 0.021
Gender
Male 42.9 (2–193); 49.4 (4.3) 14.5 (2.8–100); 16.3 (1.3) 3.4 (0.2–7.6); 3.5 (0.2)
Female 42.3 (2–200); 51.3 (4.4) 12.6 (4.3–63.4); 19.1 (2.5) 3.6 (0.4–8.1); 3.5 (0.3)
P* .417 .289 .825
H. pylori–positive (culture or IgG antibodies)
Negative 31.6 (2–200); 38.5 (5.4) 7.5 (4.3–41.3); 10.8 (1.4) 4.3 (0.4–7.9); 4.0 (0.3)
Positive 53.4 (2.4–151); 50.5 (4.4) 15.3 (6.1–94.0); 18.8 (2.3) 2.3 (0.4–8.1); 3.0 (0.2)
P* .013 <.001 .004
*Mann-Whitney test for differences in PG distribution according to gender and H. pylori status.
Figure 1. PGI/PGII ratio according to histopathologic lesion and H. pylori status. Although H. pylori infection contributes to lower values of PGI/PGII, more severe
lesions such as dysplasia have significantly lower levels with (P = .050) or without H. pylori (P = .042) infection.
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At least for intestinal-type gastric adenocarcinoma,
patients with ACG, namely, those with extensive areas of
IM changes [21,22], seem to be at risk for gastric cancer. In
Vienna, dysplasia was considered as a truly premalignant
lesion, but to our knowledge, no recommendation on the
management of patients with ACG or extensive IM exists,
mostly because studies demonstrating the cost-effective-
ness of such strategy are lacking.
This may be due to the fact that most studies tried to
assess this issue after standardized endoscopic examina-
tions and random biopsies. These procedures, even if per-
formed in different and numerous sites, may still fail to
diagnose dysplasia and cancer, both because those lesions
may be scattered and multifocal and because endoscopy, at
least for this purpose, shows a very high interobserver
variability. In our study, we decided to use an improved
endoscopic observation [18] that is reproducible and valid,
leading to a more accurate assessment of the histopatho-
logic status of gastric mucosa. However, even if an endo-
scopic method is improved [37–39], it will still be dependent
on morphologic observations of limited areas and will clearly
be badly accepted by patients.
Serum levels of PGI and the PGI/PGII ratio were used in
several studies as markers of gastric mucosal changes (as
‘‘serologic biopsy’’). The focus was mainly on the selection of
individuals with atrophic changes from the general popula-
tion, with itself as an end point of the study [12–14], or as
an associated lesion with gastric cancer to improve patients’
compliance with the gastric cancer screening program in
Japan.
In our study, we decided to evaluate this test’s consisten-
cy by estimating its usefulness even in a selected set of
patients at high risk for gastric cancer.
In fact, we observed that as changes in gastric mucosa
become more severe in terms of carcinogenesis (type II or
type III IM or low-grade neoplasia) or more extensive IM,
PGI/PGII ratio decreases significantly. In the absence of a
surface area estimate, an index of the extent of IM was
conceived as a proportion of collected specimens with IM,
based on the fact that IM evolves from the antrum–corpus
junction and the antral lesser curvature to the antral greater
curvature and distal corpus and, finally, to the greater
curvature of the proximal corpus. A significant decrease of
the PGI/PGII ratio seems to occur with extensive incomplete
IM and LGD. In fact, this should be very important, as these
are probably the more aggressive lesions leading to gastric
cancer [35].
Age, gender, time of follow-up, and H. pylori infection
status were considered in our analysis. No agreement exists
[14,16] on the influence of age and gender on PG levels, and
whenever assessment of changes in cutoff value according
to those factors was tried, either no changes were obtained
or significant losses in validity measures were noticeable.
In our sample, we did not observe any differences with
statistical significance on PG levels according to gender.
Age does not explain more than 2% of the pepsinogen serum
Figure 2. Receiver operator characteristics curves for the diagnosis of histologic lesions: for the diagnosis of HGD or cancer (grey), AUC = 0.81 (0.66–0.95, 95%
CI); for the diagnosis of lesions as severe as LGD (large dashes), AUC = 0.72 (0.58–0.85, 95% CI); and for the diagnosis of lesions more severe than extensive
incomplete intestinal metaplasia or LGD (small dashes), AUC = 0.73 (0.64–0.82, 95% CI).
Pepsinogen Validity in Intestinal Metaplasia and Gastric Dysplasia Dinis-Ribeiro et al. 453
Neoplasia . Vol. 6, No. 5, 2004
values. In fact, age seems to be related to an increase in acid
secretion in humans [40], and the decrease of PGI level
and PGI/PGII ratio found in most studies may be related
not to age but to atrophic changes diagnosed that way.
H. pylori infection, a risk factor for gastric cancer, seems
to be related to an increase of both PGI and PGII, which is
probably associated with inflammation and cytokine release
[41,42]. In our sample, we decided to define H. pylori
infection status based on culture results and serum levels
of IgG antibody to circumvent the possible ‘‘loss’’ of H. pylori
from areas with IM. In fact, as others did [43] in a previous
report, we observed [24] a negative correlation between the
extent of metaplasia and the anti–H. pylori titer. In that
report, Barbosa et al. [24] argue that as in other sets (such
as evaluation after H. pylori eradication therapy for peptic
ulcer disease) [1], noninvasive tests (namely, specific IgG
serum levels), after proper assessment of cutoff values and
their validation, may be used in the follow-up of patients with
ACG and IM. A decrease to levels considered negative may
be used to select patients for further evaluation, for instance,
through endoscopic examination. Therefore, we decided to
consider H. pylori status both to assess confounding effects
for PG levels and to evaluate any modifications made to
validity measurements according to the status of infection.
We did find a variation of PG levels related to H. pylori
infection, but as Fokuda et al. [44] did, we observed that
although H. pylori justifies some decreases in the PGI/PGII
ratio, it does not per se justify the decrease related to the
severity of lesions. Furthermore, in this study, no differences
were found in H. pylori infection status according to histo-
pathologic lesions and no significant changes occurred in
validity measurement estimates.
Several authors [11,13,16,17] reported on the relation-
ship between the serum levels of PGI and PGII as related to
mucosal changes in the stomach, mostly in asymptomatic
and/or unknown gastric mucosal lesions. In the present
Table 3. Validity Estimates of PGI/PGII Serum Level Ratio [% (CI 95%)] Either Alone or Considering H. pylori Infection as Risk Factor for the Diagnosis of
Lesions as Severe as Extensive Incomplete IM, Dysplasia, or HGD and Its Variation After (n = 136).
Diagnosis Positive Test Defined as PGI/PGII
Serum Level Ratio
Positive Test Defined as Either H. pylori Infection–Detected or
PGI/PGII Serum Level Ratio
V4 V3 V2 V4 V3 V2
Extensive IM (n = 61)
Sensitivity 80% (73–87) 66% (57–74) 36% (28–44) 84% (78–90) 74% (66–81) 59% (51–67)
49/61 40/61 22/61 51/61 46/61 36/51
Specificity 60% (51–68) 78% (71–85) 82% (75–89) 39% (31–47) 46% (37–55) 46% (37–55)
44/74 58/74 61/74 29/74 34/74 34/74
Positive predictive value 62% (54–70) 66% (58–74) 63% (55–71) 53% (44–61) 54% (45–63) 47% (38–56)
49/79 40/56 22/35 51/96 46/86 36/76
Negative predictive value 78% (71–85) 73% (65–81) 61% (53–69) 74% (66–82) 69% (61–77) 58% (49–66)
44/56 58/79 61/100 29/39 34/49 34/59
Likelihood ratio of a
positive test
1.98 (1.74–2.21) 3.00 (2.56–3.42) 2.00 (1.76–2.24) 1.38 (1.25–1.50) 1.37 (1.25–1.49) 1.09 (1.04–1.14)
Likelihood ratio of a
negative test
0.34 (0.26–0.42) 0.44 (0.35–0.52) 0.78 (0.71–0.85) 0.41 (0.32–0.49) 0.56 (0.48–0.65) 0.89 (0.84–0.94)
Dysplasia (n = 23)
Sensitivity 78% (71–85) 70% (62–78) 57% (49–65) 83% (77–89) 74% (66–82) 65% (57–73)
18/23 16/23 13/23 19/23 17/23 15/23
Specificity 46% (37–54) 65% (57–73) 81% (74–88) 31% (23–39) 38% (30–46) 46% (37–55)
51/112 72/112 90/112 35/112 43/112 51/112
Positive predictive value 23% (16–30) 29% (21–36) 37% (29–45) 20% (13–27) 20% (13–27) 20% (13–27)
18/79 16/56 13/35 19/96 17/86 15/76
Negative predictive value 91% (86–96) 91% (86–96) 90% (85–95) 90% (85–95) 88% (82–94) 86% (80–92)
51/56 72/79 90/100 35/39 43/49 51/59
Likelihood ratio of a
positive test
1.44 (1.31–1.58) 2.00 (1.76–2.24) 3.00 (2.58–3.42) 1.20 (1.12–1.29) 1.19 (1.11–1.28) 1.20 (1.12–1.29)
Likelihood ratio of a
negative test
0.48 (0.39–0.56) 0.46 (0.38–0.55) 0.53 (0.45–0.62) 0.55 (0.46–0.63) 0.68 (0.60–0.76) 0.76 (0.69–0.84)
HGD (n = 11)
Sensitivity 91% (86–96) 82% (75–89) 73% (65–81) 90% (85–95) 82% (75–89) 73% (65–81)
10/11 9/11 8/11 10/11 9/11 8/11
Specificity 45% (36–54) 63% (55–71) 79% (72–86) 31% (23–39) 38% (30–46) 45% (36–54)
55/124 77/124 97/124 38/124 47/124 56/124
Positive predictive value 13% (7–19) 16% (10–22) 22% (15–29) 10% (5–15) 11% (6–16) 11% (6–16)
10/79 9/56 8/35 10/96 9/86 8/76
Negative predictive value 98% (96–100) 98% (96–100) 97% (94–99) 97% (94–99) 96% (93–99) 95% (91–99)
55/56 77/79 97/100 38/39 47/49 56/59
Likelihood ratio of a
positive test
1.65 (1.48–1.83) 2.22 (1.93–2.50) 3.48 (2.97–3.98) 1.30 (1.20–1.41) 1.32 (1.21–1.43) 1.33 (1.21–1.44)
Likelihood ratio of a
negative test
0.20 (0.13–0.27) 0.28 (0.21–0.36) 0.34 (0.26–0.42) 0.32 (0.24–0.40) 0.47 (0.39–0.56) 0.60 (0.52–0.68)
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study, the pepsinogen test was used for the first time in our
country in a set of patients with very high a priori probability of
a positive test.
Although a systematic analysis of published reports would
probably address this test’s consistency in different popu-
lation sets more accurately, we defined the same discrimi-
native point (PGI/PGII ratio of V3) as the best cutoff, as in
other studies with very similar results.
Considering validity measurement estimates, we found
sensitivity values that may not be cost-effective for screening
purposes. However, if we consider negative predictive val-
ues even in a select high-risk sample as we did, we may
argue that in a clinical background where no clear recom-
mendations had been made until now, PGI/PGII serum level
ratio may be a useful tool [35].
We conclude that the evaluation in serum of both forms of
pepsinogens and the calculation of the PGI/PGII ratio seem
to be valid for the diagnosis of neoplastic forms, even in
individuals with a high pretest probability of atrophy. Al-
though its effectiveness needs evaluation, a management
strategy based on this test may exclude patients from
endoscopy and it may be able to noninvasively follow indi-
viduals with indolent lesions, such as ACG. Furthermore,
when used together with endoscopic examination, it may
give helpful information on the assurance and exclusion of
more advanced lesions.
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